Lymphoma (FL): Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide,
or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade
I-IIIa Follicular Lymphoma
What are the good and bad effects of using TGR-1202 and lenalidomide in combination
with the antibody, obinutuzumab?
Basic Study Information
Purpose:Location: Cancer Center
During the study, you will get either obinutuzumab plus TGR-1202, obinutuzumab plus
lenalidomide, or obinutuzumab plus the usual approach treatment for your cancer.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03269669?term=S1608&rank=1
Study Reference #: CLYM17097
Lead Researcher (Principal Investigator)
Lead Researcher: Paul Barr
Study Contact InformationStudy Coordinator: Andrew Bui
Phone: (585) 276-4405
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search